Organon & Co. (NYSE:OGN) Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC reduced its stake in Organon & Co. (NYSE:OGN - Free Report) by 59.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,486 shares of the company's stock after selling 44,716 shares during the quarter. Sterling Capital Management LLC's holdings in Organon & Co. were worth $455,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Organon & Co. by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company's stock valued at $453,593,000 after acquiring an additional 218,165 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock worth $166,391,000 after buying an additional 11,140,388 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Organon & Co. by 1.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company's stock valued at $147,634,000 after buying an additional 136,760 shares in the last quarter. LSV Asset Management raised its holdings in shares of Organon & Co. by 0.4% in the 4th quarter. LSV Asset Management now owns 7,525,076 shares of the company's stock valued at $112,274,000 after buying an additional 30,557 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Organon & Co. by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 4,260,218 shares of the company's stock worth $63,582,000 after acquiring an additional 12,110 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Morgan Stanley decreased their price target on shares of Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $20.60.

Organon & Co. Price Performance

Shares of OGN stock traded up $0.35 during mid-day trading on Thursday, reaching $11.84. The stock had a trading volume of 1,178,463 shares, compared to its average volume of 2,687,282. The company has a market cap of $3.05 billion, a P/E ratio of 3.56, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. Organon & Co. has a 12-month low of $10.45 and a 12-month high of $23.10. The business has a 50-day simple moving average of $13.99 and a 200 day simple moving average of $15.27. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.57 billion. On average, sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 9.46%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio is currently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.